Tencent Trusted Doctor Group (hereinafter referred to as “Tencent Trusted Doctor”), the largest non-public medical service platform in China, has raised $250 million in its most recent fundraising round. This round of financing was jointly led by Country Garden Holdings, Tencent, and GAW Capital. Follow investors included CMB International, Harvest Wealth, Russia-China Investment Fund, Sequoia China, SenseGain, and AVIC Trust. This was the first round of investment since the merger between Tencent Doctorwork and Trusted Doctors in 2018. CEC Capital acted as the sole financial adviser to Tencent Trusted Doctor for this round of financing.
On March 8, WM Motor Technology announced the completion of its C round of financing, securing a total of RMB3 billion. The lead investor was Baidu Inc and the follow investors included Taihang Industrial Fund and Linear Venture. The capital secured durin
China’s leading therapeutic antibody R&D company, SinoMab Bioscience Limited (“SinoMab”) just completed a Pre-IPO round of financing, securing some hundreds of millions in RMB. This round of investment was co-led by Zhongjin Zhide Equity Investment Management (an investment arm of China International Capital Corporation Limited) and Apricot Capital. SinoMab also announced that it will begin work on its IPO. CEC Capital served as the sole financial adviser to SinoMab during this round of financing.
Taicang, Suzhou, January 2, 2019/PRNewswire / - Connect Biopharmaceuticals, a clinical-stage company that discovers and develops novel immune modulators for the treatment of autoimmune diseases and inflammation, today announces the completion of a $55 mil
In December 2018, Shanghai Cell Therapy Group Co., Ltd. (the “Company”), a leader in China’s cell therapy medical industry, announced the completion of its C round of financing, raising RMB 925 million (US$134M). The financing was co-led by China Pacific Insurance, Haier Capital, and China Industrial Asset Management Limited, with participation from existing investors Legend Capital, Anting People's Government, and Ningbo Yuanhui. The Company used this round of financing to bring on-board strategic investors that can provide significant business synergies across the various parts of its business. The capital will be used for R&D of innovative cellular technologies and treatments, development of cryopreservation technologies, and the construction of high-end cancer hospitals. CEC Capital served as the exclusive financial adviser for this round of financing.
Three months after announcing the completion of its last round of financing, Ucommune just released news that it smoothly completed its most recent D round of financing. Ucommune is recognized as one of the top shared office space service providers and a “unicorn” in China. Today Ucommune publicly announced that the funds raised during this D round of financing set a record for the company with a total investment amount of USD 200 million. This marks the completion of another large-scale transaction within the shared office space industry. This D round of financing was completed with All-Star Investment Fund as the leading investor and CEC Capital as the following investor. CEC Capital served as the sole financial adviser to Ucommune during this round of financing.